Advice
Following a full submission
fondaparinux (Arixtra®) is accepted for use within NHS Scotland for the treatment of unstable angina or non-ST segment elevation myocardial infarction in patients for whom urgent (<120minutes) invasive management (Percutaneous Coronary Intervention) is not indicated.
Fondaparinux was shown to be non-inferior to a low molecular weight heparin in preventing death, myocardial infarction or refractory ischaemia in the nine days following onset of symptoms. Fondaparinux also had a significantly lower major bleeding event rate than a low molecular weight heparin.
Download detailed advice60KB (PDF)
Medicine details
- Medicine name:
- fondaparinux (Arixtra)
- SMC ID:
- 420/07
- Indication:
- Unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI)
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 December 2007